BBIO — BridgeBio Pharma, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1743881 ·
Last close
$76.80
Market Cap
$14.96B
52W High
$93.42
52W Low
$62.50
ADV30
2,789,347
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 353,171,000 332,721,000 -11,639,000 -56,710,000 2,161,786,000 1,533,363,000 3,815,291,000
Jun 2026 243,676,000 228,630,000 -107,079,000 -152,216,000 1,217,299,000 677,911,000 3,723,192,000
Mar 2026 194,515,000 184,576,000 -105,956,000 -164,043,000 1,370,981,000 879,891,000 3,639,856,000
Dec 2025 154,178,000 146,071,000 -128,431,000 -192,863,000 936,025,000 570,119,000 3,012,606,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-368,970,000
Investing CF
$-2,593,000
Financing CF
$1,261,955,000
CapEx
$-835,000
Dividends Paid
—
Buybacks
$-273,363,000
EPS Diluted TTM
$-3.04
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-4,194,163,000
Inventory
$59,718,000
Receivables
$375,089,000
ST Investments
$5,492,000
EBIT TTM
$-363,179,000
Pretax Income TTM
$-576,468,000
Interest Exp TTM
$213,289,000
Analysts
20

Yahoo Snapshot (yfinance, live)

Total Revenue
$945,539,968
EBITDA
$-348,361,984
Free Cash Flow
$-302,881,248
Enterprise Value
$17,390,876,672
Total Cash
$1,538,855,040
Total Debt
$3,378,097,920
Shares Out
194,800,782
Trailing EPS
$-3.03
Book Value
$-13.29
ROE
—
ROA
-14.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 502,076,000 -502,064,000 -724,931,000 936,025,000 3,012,606,000 -2,086,610,000 -445,910,000
Dec 2024 221,902,000 -577,368,000 -535,762,000 919,338,000 2,376,950,000 -1,467,904,000 -520,726,000
Dec 2023 9,303,000 -599,444,000 -643,202,000 546,380,000 1,888,915,000 -1,354,257,000 -527,720,000
Dec 2022 77,648,000 -468,437,000 -481,183,000 623,036,000 1,867,960,000 -1,254,617,000 -419,494,000

TTM Snapshot

Revenues TTM
$713,069,000
NetIncome TTM
$-691,865,000
OpCashFlow TTM
—
Assets (Latest)
$1,217,299,000
Forward EPS
$-0.05

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $70.00 · spot: $78.01 · call volume: 578 · put volume: 1,212
Expected Move to 2027-01-15: ±$22.05 (28.27%) — implied range $55.96 – $100.06 · ATM straddle on $77.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
JAZZ Jazz Pharmaceuticals plc $15.45B $240.71 —
ELAN Elanco Animal Health Inc $12.92B $25.85 —
ASND Ascendis Pharma A/S $17.84B $271.19 —
RDY DR REDDYS LABORATORIES LTD $12.32B $14.79 —
BMRN BIOMARIN PHARMACEUTICAL INC $11.33B $58.51 —

News headlines (Yahoo Finance, 1h cache)

BridgeBio Pharma (BBIO) Could Be 212% Overvalued After New Acoramidis Data
2026-11-19 05:13 · Yahoo
BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
2026-11-11 12:30 · Yahoo
Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery
2026-11-09 14:31 · Yahoo
BridgeBio to Participate in November and December Investor Conferences
2026-11-09 12:30 · Yahoo
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 21:01 · Yahoo
BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026
2026-11-03 12:30 · Yahoo
Should You Invest $1,000 in BridgeBio Pharma Right Now?
2026-11-02 12:05 · Yahoo
What Is BridgeBio Pharma (BBIO) Betting On With Three FDA Priority Launches?
2026-11-01 21:10 · Yahoo
BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS Says
2026-10-30 17:04 · Yahoo
BridgeBio (BBIO) Q3 2026 Earnings Call Transcript
2026-10-30 14:29 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.